
BRAF (gene) - Wikipedia
BRAF is a human gene that encodes a protein called B-Raf. The gene is also referred to as proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B, while the protein is more …
BRAF Mutation and Cancer - Johns Hopkins Medicine
2 days ago · BRAF gene mutations can cause normal cells to become cancerous. Learn about the mutation, the types of cancer it can cause and the treatments available.
BRAF
Apr 16, 2024 · In this review, we cover the current understanding of BRAF mutations and associated clinical characteristics in patients with metastatic NSCLC, approved and emerging treatment options, …
BRAF and Lung Cancer - American Lung Association
Dec 2, 2025 · BRAF is one type of lung cancer biomarker. BRAF is the name of both a gene and a protein. The BRAF protein helps control cell growth. When there is a mutation in the BRAF gene, it …
BRAF Mutation: Cancer Types, Testing, Treatment - Verywell Health
Sep 15, 2025 · BRAF mutations are present in many melanomas as well as some lung cancers, colon cancers, and more. Learn about the basics, testing, and treatment.
BRAF gene: MedlinePlus Genetics
The BRAF gene provides instructions for making a protein that helps transmit chemical signals from outside the cell to the cell's nucleus. Learn about this gene and related health conditions.
BRAF Gene - GeneCards | BRAF Protein | BRAF Antibody
Jan 14, 2026 · BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase) is a Protein Coding gene. Diseases associated with BRAF include Lung Cancer and Cardiofaciocutaneous Syndrome 1. …
Biology and Clinical Management of Non-V600 BRAF Alterations
Jan 19, 2026 · Beyond point mutations, other BRAF alterations (e.g., gene fusions, deletions, and amplifications) have been identified in treatment-naive tumors and in the context of acquired …
FDA Approves Guardant360 CDx Diagnostic For Some With Colorectal …
4 days ago · The FDA approved Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from Braftovi with Erbitux and …
Guardant Health Receives FDA Approval for Guardant360® CDx as …
The accelerated approval was supported by data from Pfizer’s Phase 3 BREAKWATER trial, which evaluated encorafenib-based regimens in previously untreated patients with BRAF -mutated …